J Wan, S Xing, L Ding, Y Wang, C Gu, Y Wu, B Rong… - Cell reports, 2020 - cell.com
Summary Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than …
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has …
E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
B Ju, Q Zheng, H Guo, Q Fan, T Li, S Song, H Sun… - Cell Research, 2022 - nature.com
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants is still a pandemic raging across the …
DJ Sheward, P Pushparaj, H Das, C Kim, S Kim… - bioRxiv, 2022 - biorxiv.org
The SARS-CoV-2 Omicron Variant of Concern (B. 1.1. 529) has spread rapidly in many countries. With a spike that is highly diverged from that of the pandemic founder, it escapes …
Abstract SARS-CoV-2 Omicron variant XBB. 1.5 has shown extraordinary immune escape even for fully vaccinated individuals. There are currently no approved antibodies that …
W Zhan, X Tian, X Zhang, S Xing, W Song… - Journal of …, 2022 - Am Soc Microbiol
The continuous emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses new challenges in the fight against the coronavirus disease …
Antibodies elicited in response to infection undergo somatic mutation in germinal centers that can result in higher affinity for the cognate antigen. To determine the effects of somatic …